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Cardiovascular (CV) diseases are a serious concern in rheumatoid arthritis (RA), accounting for approximately one-third to one-
half of all RA-related deaths. Besides the attempts to identify new risk factors, the proper management of traditional CV risk factors
such as dyslipidemia should become a priority in the periodic evaluation of every RA patient. Atherogenic index has been suggested
to be less susceptible to disease activity variation during large periods of time, making him more attractive to be used in CV risk
prediction in this group of patients as compared to individual lipids concentrations. Nevertheless, inflammation may negatively
impact HDL antiatherogenic properties, suggesting that HDL function assessment is of particular importance when predicting CV
risk in these patients. A tight control of inflammation becomes therefore crucial for a successful CV risk management. The present
paper debates these hypotheses focusing on the eﬀects of therapy with biologicals on the above mentioned parameters.
1. Introduction
Cardiovascular (CV) diseases are a serious concern in
patients with chronic inflammatory diseases. For patients
with rheumatoid arthritis (RA), it represents the leading
cause of death, accounting for approximately one third to
one half of all RA-related deaths [1, 2]. In order to decrease
this incidence, risk factors need to be identified in the first
place. Intriguingly, previous studies have suggested that the
augmented CV burden found in RA patients seems not to
be fully explained by traditional CV risk factors, such as
dyslipidemia, hypertension, smoking, and physical inactivity
[3]. Consequently, factors leading or deriving from the
chronic inflammation have been suggested to be responsible
for the augmented risk [4–6]. Until nowadays, however, no
such factor is proved to solidly confirm this hypothesis.
Recently, several studies have suggested that it might
have been enough room to improve the cardiovascular
profile of RA patients only by focusing on the traditional
risk factors. Impaired during the periods of active disease,
physical activity could be importantly improved by a better
disease control as suggested in the recent international
guidelines, consequently improving CV profile [7]. Using
diﬀerent methods to assess the risk of developing CVD,
Toms et al. have recently reported that between 2% and 25%
of RA patients who should receive a lipid-lowering drug
(statin) according to their calculated risk do not actually
use this medication [8]. The percentages may even increase
from 7% to 30% if the 1.5 multiplier factor is applied as
recently recommended [9]. Despite its limitations, the study
emphasizes the possibility of suboptimal therapy of tradi-
tional risk factors in RA patients, providing a solid alternative
to improve CV pattern in RA. Finally, inflammation may
alter traditional CV risk factors including lipids pattern, both
at the concentration and composition level [10, 11]. This
observation has recently led to the concept of “smaller slice
of a bigger pie,” which emphasizes that due to the presence
of chronic inflammation, the relative contribution of these
factors to the overall CV risk in RA is diﬀerent than in the
general population. All these data suggest that despite the
progresses made in the past years, traditional CV risk factors
such as dyslipidemia are not yet entirely understood and
appropriately managed in patients with RA.
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Traditionally, the atherogenic lipid profile is made up
of increased TC, LDL, TG, and decreased HDL. In chronic
inflammatory diseases such as RA, however, diﬀerent con-
centrations of lipids can be found throughout diﬀerent stages
of the disease: increased TC and LDL in the years prior
to disease onset, reduced levels of TC and HDL-C during
early active disease, and diﬀerent patterns in established RA
[12, 13]. Hence, due to the variable degree of chronic inflam-
mation, the individual lipid concentrations may frequently
fluctuate during the course of disease making the impact of
such changes on CV risk less clear. Nevertheless, the diﬀerent
cholesterol fractions seem to fluctuate together in the same
direction. In line with this, recent studies have suggested
that the atherogenic index (AI—the ratio TC :HDL) is less
susceptible to disease activity fluctuations in RA. Therefore,
one can hypothesize that AI may be more appropriate
to be used to assess the relative contribution of lipids to
the CV risk in RA patients than individual cholesterol
fractions measurements. Finally, inflammation may not only
modulate the levels but also the composition of lipoproteins.
In line with this, our group and others have shown that
HDL becomes less antiatherogenic in RA patients, and this is
associated with inflammatory status [10, 11]. Therefore, we
suggest that in chronic inflammatory conditions, HDL anti-
atherogenic properties (i.e., antioxidant, cholesterol reverse
transport) may prove to be a valuable alternative marker to
predict the development of atherosclerosis and CV burden in
RA patients.
Recent recommendations for the treatment of RA pro-
pose a tight control of disease activity to achieve rapid
remission in the early disease stage. Controlling the inflam-
matory process is likely to favorably impact CV risk. In
line with this, new therapeutic strategies have been recently
elaborated, encouraging the use of aggressive antirheumatics,
including biologicals, earlier in the course of disease [7].
The consequence will be that an increasing number of RA
patients will be treated in the future with these drugs. Appro-
priate knowledge about their eﬀects on cardiovascular risk
factors, including lipid pattern, would therefore be of great
importance. Several previous publications have addressed
the eﬀects of biologicals on the lipid profile, concentrat-
ing on individual lipid levels/changes. However, important
questions regarding the overall atherogenic capacity of the
lipid profile and the subsequent impact on the cardiovascular
risk remain largely unanswered. The present paper focuses
on the relation between the therapy with biologicals and
atherogenic index as a more suitable parameter in RA to
address CV risk in this population. In addition, data on HDL
function in the same context will be discussed.
2. Methods
2.1. Literature Search and Study Selection. We conducted
a literature search in Medline via PubMed for articles
published up to May 2012. The MeSH terms used were
anti-TNF, infliximab, adalimumab, etanercept, tocilizumab,
rituximab, and rheumatoid arthritis (MeSH). These were
combined with cholesterol (MeSH), lipids, HDL, and
atherogenic index. Articles were selected if they met all
of the following criteria: (a) clinical trial or observational
study that included ≥10 patients with rheumatoid arthritis
(except for rituximab studies), (b) treatment with infliximab,
adalimumab, etanercept, tocilizumab, or rituximab, and (c)
values of total cholesterol (TC), HDL, and atherogenic ratio’s
taken before and after treatment. The search was further
restricted to English language full-text articles. Studies were
manually selected by two authors (CP, EA) by screening the
title, keywords, and abstract, using the eligibility criteria. If
possibly eligible, full-text articles were retrieved and judged
using the eligibility criteria. The inclusion of articles was
determined by consensus.
2.2. Data Presentation. Due to the heterogeneity of study
populations, type of treatment, dosages, follow-up time,
outcome measures, and statistical analysis, a meta-analysis
was not performed. Hence, a narrative summary of the
results is provided. The primary summary measure used
to compare results was the diﬀerence in AI for short-term
studies (<6 months) and long-term studies (>6 months).
Results regarding anti-TNFα, anti-IL-6R, and anti-CD20
therapy are discussed. No additional quality assessments
were performed. Sample size, diﬀerences in type of treatment
and dosages, and study duration were taken into considera-
tion when comparing results.
3. Results and Discussion
In total, there were 105 records identified. Of them, 4 were
excluded because they were not written in English, 5 were
case reports, 56 were oﬀ topic, 3 were themselves reviews, and
4 studies investigated less than ten RA patients (see inclusion
criteria). At the end of the selection procedure, 33 full-text
articles met the eligibility criteria and were considered for
this paper (Figure 1). Of the 33 studies, the vast majority
concerned anti-TNF users, usually infliximab, adalimumab,
and etanercept [11, 14–32], 8 studies concerned tocilizumab
(including three randomized clinical trials) [21, 33–39], and
5 studies investigated rituximab eﬀects on lipids pattern
[14, 40–43]. Data on other biologicals, including abata-
cept, anakinra, golimumab, or certolizumab have not been
addressed here due to their very limited and preliminary
character.
3.1. Anti-TNF Agents. TNF-α is a proinflammatory cytokine
which plays a pivotal role in both RA and atherosclerosis
pathogenesis. A beneficial eﬀect of anti-TNF treatment on
CV morbidity and mortality in RA has been demonstrated
[44]. Many studies have investigated the eﬀects of anti-TNF
medication on the lipid profile, yet the majority of studies
comprise small groups of patients with a short followup. This
paper will further focus on studies concerning infliximab,
adalimumab, and etanercept. As previously mentioned, it
will separately address the short and long-term eﬀects,
respectively, for all three drugs taken together. Finally, the
eﬀects on HDL function will be summarized.
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105 articles
33 articles
Exclusion: n = 72
• 56 out-off topic
• 3 reviews
• 5 case reports
• 4 not English
• 4 (N < 10)
Figure 1: Flowchart.
3.1.1. Short-Term Studies. Short-term studies demonstrate
primarily significant antiatherogenic changes, particularly in
TC and HDL levels, whereas TG and LDL concentrations
often remain unchanged. Interestingly and of importance
for our present paper, changes in the atherogenic index
(TC :HDL) and other ratios (LDL :HDL, ApoB : ApoA-1)
have also been noticed. Our group found a significant
decrease of approximately 8% in both LDL :HDL and
the TC :HDL ratio after two weeks of treatment with
adalimumab in a group of 33 RA patients as compared to
placebo [24]. Our results have been further confirmed by
a recent study in 50 RA patients receiving adalimumab: AI
baseline—16 weeks was 3.33 (0.93) versus 3.15 (0.85), P =
0.034 [32]. A significant decrease in the apoB : apoA-1 ratio
has been also reported (P = 0.014). A trend towards a
more pronounced eﬀect on HDL in the responders group
has been noticed together with an association with disease
activity changes (r = −0.31, P = 0.03). Similar results have
been reported by Jamnitski et al., who found a significant
decrease in the ApoB : ApoA-1 ratio over a period of 3
months [19] in 292 RA patients receiving TNF blockade.
Interestingly, this change has been found only in good and
moderate EULAR responders. Nevertheless, some further
studies reported opposite results (Table 1). Following 45 RA
patients treated with infliximab during a period of almost
6 months, our group reported a significant increase in the
TC :HDL ratio [11] at the end of this period. These findings
were supported by Dahlqvist et al. [17], who reported an
increase of 8% and 9% in the LDL :HDL and TC :HDL ratio,
over the same time period in 52 RA patients treated with
infliximab. Other studies did not indicate any change in the
atherogenic index or other ratios within a period of 3 or
6 months of anti-TNF therapy [14, 16, 18, 21, 25, 26, 28,
30, 31], although individual lipid levels were often found to
increase in the initial months of treatment [25, 26, 30, 31].
Studying 56 patients with RA receiving infliximab for 30
weeks, Allanore et al. found no changes in the atherogenic
index despite a significant stable increase of HDL and TC.
They also noticed no relations between response to therapy
and lipid pattern modifications [15]. Similar findings have
been reported by Seriolo et al. in 34 consecutive RA patients
treated with various TNF blockers (n = 16 for etanercept,
n = 14 for infliximab, and n = 4 for adalimumab) for
24 weeks [26]. The authors reported however on a relation
between changes in HDL and disease activity (DAS28) by the
end of the study (r = −0.52, P < 0.01), without making
any reference to response rate. These findings are in line
with those from a previous study, indicating a correlation
between the decrease in disease activity and the increase in
HDL 6 weeks after therapy with infliximab has been initiated
[31]. This association remained after adjusting for changes in
prednisone dose, age, gender, and disease duration. Although
the mean atherogenic index did not change, changes in
DAS28 were significantly associated with changes in the
atherogenic index in the period 0 to 2 weeks. However, this
association disappeared when the whole study period (6
weeks) has been considered.
A few more studies should be mentioned, which did
investigate the eﬀects of TNF blockade on lipids pattern
in RA patients, however, without entirely fulfilling our
inclusion criteria. Several investigators pulled together data
from patients with RA and other inflammatory conditions
such as ankylosing spondylitis [20]. In this setting, they
found no changes in AI after 6 months of therapy with
infliximab. Other studies provided data only on individual
lipids without atherogenic index or other ratios [22, 27,
29]. Finally, in an elegant study, Gonzalez-Juanatey et al.
investigated endothelial function and atherogenic index in
a small group (N = 8) of RA patients who failed on
infliximab and were now treated with adalimumab. Besides
rapid improvement of endothelial function, a significant
decrease of the atherogenic index was observed at week 2
(3.30 ± 0.55) and at week 12 (3.28 ± 0.48) when compared
with baseline atherogenic index result (3.52± 0.50) (P value
for both comparisons = 0.012). This was associated with a
decrease in disease activity and inflammation status [45].
The apparent heterogeneity of these results may be due
to several factors. Firstly, it mostly concerns small-group
studies enrolling RA patients from diverse countries with a
distinctive health care system and lifestyle habits, including
physical activity (biking for the Dutch population) [11, 23–
25, 31, 32] and alimentation (fish-reach diet in Northern
Europe, Mediterranean diet in the Southern Europe) [14,
15, 17, 18, 20, 26, 28]. Secondly, a diﬀerence between the
anti-TNF agents may be present, leading to a more pro-
atherogenic profile in the case of infliximab [11, 17], with
milder eﬀects for adalimumab and etanercept [19, 24, 32].
Thirdly, gendermay also contribute to this heterogeneity, our
group reporting a more pronounced eﬀect on lipid pattern
in male RA patients. Accordingly, total cholesterol and HDL
increased more markedly 6 months after starting infliximab
(P < 0.04), translating into a tendency to increase of the
atherogenic index [25]. Finally, the response rate and the
degree of response to anti-TNF therapy is likely to impact
the changes in lipid profile. Though several studies have
addressed the association between changes in disease activity
or inflammatory status and changes in lipids concentrations,
only a few investigated the association between the latter
and response according to established criteria (EULAR/ACR)
[19, 25, 32]. These studies suggest that the atherogenic index
tends to increase more in nonresponders as compared to
responders [25], or to decrease only in responders [19, 32].
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Table 1: Short-term eﬀects of anti-TNF drugs on atherogenic index and other ratios.
Study Drug Number of patients Duration
Eﬀect
AI Other ratios
Popa et al. [24] ADA 33 2wk L LDL :HDL
Wijbrandts et al. [32] ADA 50 16wk L apoB : apoA-1
Gonzalez-Juanatey et al.
[45]
ADA 8 12wk L —
Kume et al. [21] ADA/ETN 42 24wk n —
Seriolo et al. [26] ADA/ETN/IFX 34 24wk n —
Soubrier et al. [28] ADA/ETN/IFX 29 14wk n apoB : apoA-1
Jamnitski et al. [19] ETN 292 16wk L apoB : apoA-1
Allanore et al. [15] IFX 56 30wk n LDL :HDL
Popa et al. [11] IFX 45 24wk H —
Dahlqvist et al. [17] IFX 52 24wk H —
Popa et al. [25] IFX 55 24wk H —
Tam et al. [30] IFX 19 14wk n LDL :HDL
Vis et al. [31] IFX 69 6wk n —
Engvall et al. [18] IFX 40 14wk — apoB : apoA-1
Ajeganova et al. [14] ADA/ETN/IFX 162 24wk — apoB : apoA-1
Curtis et al. [16] not specified 289 8wk L —
ETN: etanercept, ADA: adalimumab, IFX: infliximab, AI: atherogenic index, wk: weeks, L: lower, n: neutral, H: higher.
3.1.2. Long-Term Studies. During the first year of treatment
with anti-TNF agents, lipid concentrations tend to increase,
with some reporting a return to baseline levels after an initial
increase [23]. Despite a constant dosage of the anti-TNF
drug, changes in AI reported by short-term studies are often
not sustained over longer periods of time. Using etanercept
in a group of 292 RA patients, Jamnitski et al. found a more
pronounced decrease of apoB : apoA-1 ratio 4 months after
therapy has been initiated as compared to one year time-
point, whereas TC :HDL ratio remained similar throughout
study period [19]. The authors have also performed an
analysis in patients who responded and patients who did not
respond to the therapy according to the EULAR response
criteria. There was a trend towards a lower AI both 4
months as well as one year after starting etanercept in the
responders subgroup as compared with the nonresponders,
reaching significance in the case of apoB : apoA-1 ratio (P =
0.005). Wijbrandts et al. also reported an improvement of
the atherogenic index 52 weeks after adalimumab has been
started in a group of 44 RA patients [32], with apoB : apoA-
1 ratio decreasing with 7% (P = 0.05) and TC :HDL ratio
with 4% (P = 0.27). Of note, both ratios reached statistical
significance 16 weeks after starting adalimumab (P = 0.014
and P = 0.034, resp.) [32]. In contrast, in a case-control
study of 52 established RA patients and 70 early RA patients,
Dahlqvist et al. reported that the LDL :HDL and TC :HDL
ratios significantly worsened one year and even two years
after infliximab was started: 9.2% and 10.4%, respectively
[17]. In line with this, our group found a significant increase
in the TC :HDL ratio in a group of 55 RA patients treated
with infliximab: 9% after 6 months (P = 0.02) and 4% after
12 months (P = 0.05) [25]. In the same study, LDL :HDL
ratio did not significantly changed over time. Peters et al.
found no change in the apoB : apoA-1 ratio and TC :HDL
ratio, respectively, in a group of 80 RA patients treated with
infliximab for a period of 48 weeks [23]. Interestingly, they
observed that changes in prednisone dose were related to
changes in HDL and TC, with a relatively greater impact on
HDL, resulting in a inverse association between prednisone
dose and atherogenic index (TC :HDL and apoB : apoA-1)
[23]. Finally, in a large study involving diﬀerent anti-TNF
agents (infliximab, adalimumab, and etanercept), Ajeganova
et al. found no changes in apoB : apoA-1 ratio in all three
subgroups according to the drug, 12 months after therapy
has been initiated [14]. Similar results have been previously
reported by Engvall et al., who observed no change in
apoB : apoA-1 ratio between 3 months and 2 years of
followup [18]. Both studies report no data on TC :HDL
index.
Despite apparent discrepancy, some trends may be
depicted when analyzing these long-term eﬀects of anti-
TNF drugs on lipids in patients with RA. These trends
become clearer when focusing on atherogenic index, which
demonstrates therefore to be superior to individual lipid
concentrations in this respect (Table 2). Therapy with
etanercept or adalimumab seems to have a positive impact
on atherogenic index, although this improvement does not
always reach statistical significance [19, 32]. In contrast,
the use of infliximab may worsen lipid ratios on the long
term [17, 25], though some report a neutral eﬀect [23].
Nevertheless, a rapid and sustained control of disease activity
as in the case of responders would be associated with better
ratios as compared to non-responders, even in those patients
treated with infliximab [23]. Alternatively, the concomitant
use of prednisone may influence atherogenic index. Given
the prognostic value of these ratio for future CV events,
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it is likely that these changes are clinically relevant and
may contribute to the decreased incidence of myocardial
infarction and other CV events observed with anti-TNFα
treatment in RA.
3.1.3. Anti-TNF Therapy and HDL Function. The link
between HDL and cardiovascular disease risk is far more
complex than originally thought. This may be explained
by the inherent heterogeneity of HDL particles in terms of
composition, structure, and biological function. Emerging
evidence suggests that for instance small dense protein-rich
HDL3 particles are less capable of protecting LDL against
oxidative modification [46]. This has led some to propose
that the functionality of HDL may be as relevant as plasma
levels of HDL to cardiovascular risk assessment [47, 48]. In
the same context, a number of studies have demonstrated
that inflammation is able to negatively impact the anti-
atherogenic properties of HDL [49]. The issue becomes of
interest thus in the case of patients suﬀering from chronic
inflammatory diseases, such as RA.
In a study on 48 RA patients, which also included patients
with SLE and healthy controls,McMahon et al. demonstrated
for the first time the presence of a pro-inflammatory HDL
in this group of patients [10]. About 20% of RA patients
were likely to have such an HDL, as compared to 4% of
healthy controls. HDL function tended to correlate with ox-
LDL concentrations (r = 0.355). Inflammatory markers and
prednisone dosage have been shown to be associated with a
proinflammatory HDL. Interestingly, the authors found no
association between HDL function (proinflammatory) and
HDL concentrations, an observation which has been recently
confirmed by an elegant study in the general population [47].
Statins may reverse the pro-inflammatory HDL in a small
group of RA patients during a period of 12 weeks [50]. This
improvement was not entirely associated with a decrease in
inflammatory state. It was further indicated that the pro-
inflammatory function of HDL in RA might be due to a
diﬀerent composition as compared with anti-inflammatory
HDL (51), including a lower LCAT activity and higher MPO
activity. Nevertheless, the study does not provide suﬃcient
evidence to support the standard use of statins in patients
with RA.
Our group has investigated for the first time the eﬀects
of anti-TNF therapy on HDL antiatherogenic function. We
found that infliximab is able to improve HDL antioxidative
capacity, an eﬀect that was sustained 6 months after anti-
TNF therapy has been initiated [11]. It is still unclear how
stable these eﬀects are further in the course of therapy and
whether they are solely due to TNF blockade or more likely
to reflect the overall inflammatory suppression achieved in
these patients. Recently, we observed that HDL subfractions
are modified in RA patients, especially in women [51],
reinforcing again the importance and in the same time the
complexity of HDL status in these patients with respect to
their cardiovascular risk. Whether anti-TNF drugs are able
to restore this detrimental HDL profile remains a subject for
further investigations.
3.2. Anti-IL6 Agents. Interleukin (IL6)- is another cytokine
that plays a key role in the pathogenesis of chronic inflam-
matory diseases. Recently, the therapeutic blockade of its
receptor proved to eﬃciently suppress disease activity in
patients with RA [33–35, 37, 39]. Owing to the increased
cardiovascular risk and anti-TNF experience, trials investi-
gating the eﬀects of tocilizumab (TCZ), the IL-6 receptor
(IL-6R) antagonist in patients with RA have included for
the first time the impact of the therapy on the lipid pattern
as part of the safety analysis of the drug. An increase of
individual lipid concentrations has been constantly reported
with TCZ [37, 38]. Nevertheless, detailed results regarding
the eﬀect of treatment on the atherogenic index could
not be derived from all of the studies (Table 3). Maini et
al. reported that lipids levels increased initially and then
stabilized and did not continue to increase during the
treatment period, which is comparable to the eﬀects reported
in anti-TNF studies. Importantly, the mean atherogenic
index remained largely unchanged and was reduced to below
its initial level by the 20-week follow-up visit in the groups
receiving 8mg/kg of TCZ [37]. In another trial by Emery
et al., 20-week therapy with TCZ resulted in higher rate
of more than 30% increase in LDL/HDL ratio in patients
receiving the drug as compared to controls: 22.2% (TCZ
8mg/kg), 19.1% (TCZ 4mg/kg), and 10,1% (controls),
respectively [33]. In contrast, comparable proportions of
patients had greater than 30% increase in the apoB/apoA
ratio: 11.6% (TCZ 8mg/kg), 9.4% (TCZ 4mg/kg), and 9.7%
(controls), respectively. No acute cardiovascular event has
been reported during the study period. In the OPTION
study comparing two TCZ regimens with placebo, Smolen
et al. report similar results [39]. Increases in the ratio of
total cholesterol to HDL of more than 30% above baseline
were observed in 17% of patients treated with TCZ 8mg/kg,
8% of patients receiving TCZ 4mg/kg and 5% in the
placebo group. Comparable apoB/apoA ratio between the
groups have been reported however. One last trial adds to
strengthen the previous presented data (TOWARD study)
[34]. It compared patients receiving TCZ 8mg/kg and a
DMARDwith patients receiving a DMARD and placebo. The
authors indicate increases of more than 30% in the TC/HDL
ratio in 12% and 7% of patients in the TCZ and control
group, respectively, and increases of more than 30% in the
LDL/HDL ratio in 20% and 12% of patients, respectively.
Again, no significant changes in the apoB/apoA ratio have
been noticed in both groups. Finally, Jones et al. compared
the monotherapy with TCZ and methotrexate in a group of
673 RA patients (AMBITION study) [35]. They report no
data on atherogenic index during the 24 weeks of therapy.
It was however noted that TCZ is more prone to disturb
lipid pattern as compared to methotrexate and leads to
LDL and triglycerides elevations. In an observational study,
Kawashiri et al. noticed no changes in the ApoB/ApoA-1
and TC/HDL ratio despite an increase of individual lipids
in a small group of RA patients treated with TCZ for 12
weeks [36]. Similar findings have been reported by Kume
et al., who found no changes in TC/HDL ratio 24 weeks
after starting tocilizumab in 22 RA patients, despite sustained
increase of both TC and HDL alone [21]. Interestingly,
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Table 2: Long-term eﬀects of anti-TNF drugs on atherogenic index and other ratios.
Study Drug Number of patients Duration
Eﬀect
AI Other ratios
Jamnitski et al. [19] ETN 292 1 year n apoB : apoA-1
Wijbrandts et al. [32] ADA 50 1 year n apoB : apoA-1
Dahlqvist et al. [17] IFX 52 2 years H —
Popa et al. [25] IFX 55 1 year H LDL :HDL
Peters et al. [23] IFX 80 1 year n apoB : apoA-1
Ajeganova et al. [14] ETN/ADA/IFX 162 1 year — apoB : apoA-1
Engvall et al. [18] IFX 18 2 years — apoB : apoA-1
ETN: etanercept, ADA: adalimumab, IFX: infliximab, AI: atherogenic index, n: neutral, H: higher.
Table 3: Eﬀects of tocilizumab on atherogenic index and other lipid
ratios.
Atherogenic index Study (ref), patients (N), and lipid ratio’s
Higher
Emery et al. [33] (N = 338) LDL/HDL;
Genovese et al. [34] (N = 803) TC/HDL,
LDL/HDL;
Smolen et al. [39] (N = 418) TC/HDL
Neutral
Kume et al. [21] (N = 22) TC/HDL;
Kawashiri et al. [36] (N = 19) TC/HDL,
apoB/apoA-1;
Maini et al. [37] (N > 50) TC/HDL
N.A. Jones et al. [35]; Schultz et al. [38]
N.A: not assessed.
the authors noticed that the increase in TC in the TCZ group
has been higher than in the patients receiving adalimumab or
etanercept, reaching statistical significance (TCZ versus ETN
P = 0.024, TCZ versus ADA P = 0.032). Although the first
of its kind by directly comparing three diﬀerent biologicals
with respect to endothelial dysfunction and lipid pattern, the
results of the study should be interpreted with caution given
the relative low number of patients enrolled in each group
(approximately 20).
Overall, the present experience with tocilizumab appears
to suggest a certain detrimental eﬀect on lipids pattern,
translated into a higher percentage of patients with a
significant increase in the atherogenic index—TC/HDL and
LDL/HDL [33, 34, 39], whereas apoB/apoA-1 ratio remains
stable throughout the therapy [33, 36, 39]. These lipid
modifications led in several cases to the start of therapy with
lipid-lowering agents. It is still unclear if long-term treatment
with TCZwould reverse these detrimental eﬀects and achieve
sustained improvements in AI. To our knowledge, no studies
have investigated the eﬀect of TCZ on the HDL cholesterol
function. Given the emerging importance of this factor
in CVD risk assessment, future studies on this issue are
warranted.
3.3. Rituximab. Up to date, there are few studies investi-
gating the eﬀects of newer biologicals on lipids pattern in
RA patients. Rituximab, a B-cell depletion drug, targeting
the CD20 positive B lymphocytes, has been so far scarcely
investigated for its eﬀects on atherogenic index and HDL
composition, as compared to anti-TNF drugs. In a small
group of RA patients, Gonzalez-Juanatey et al. investigated
for the first time the eﬀects of rituximab on lipid param-
eters [40]. The authors have found a slight, nonsignificant
increase in HDL levels both 2 weeks (56 ± 11mg/dl) and
6 months (57 ± 15mg/dl) compared to baseline (52 ±
11mg/dl), whereas total cholesterol increased only 2 weeks
after starting rituximab (211 ± 42mg/dl versus 191 ±
37mg/dl). No direct information on atherogenic index has
been provided. In another study, Kerekes et al. found an
increase in HDL levels with 14.3%, 33.1%, and 35.4% as
compared to baseline, at 2, 6, and 16 weeks, respectively,
after rituximab has been initiated [41]. At sixteen-week
time-point, the diﬀerence reached significance (P = 0.035).
Interestingly, total cholesterol tended to decrease without
significance, throughout study period. This may suggest a
decrease in the atherogenic index. The results are likely
in line with the previous ones, yet the limited number of
patients investigated (n = 5) makes their interpretation
diﬃcult. The first larger study on this issue comes from
Ajeganova et al. [14]. The Swedish group investigated the
eﬀects of various biologicals on lipids pattern in 215 RA
patients receiving therapy with various biologicals, focusing
on apolipoproteins (apoA and apoB) and their ratio. The
investigators found that in the rituximab-treated group (n =
53) apoA-1 levels increased throughout the study with 0.09
± 0.32 g/L (P = 0.022, followup of 6 months) and 0.09 ±
0.32 g/L (P = 0.06, followup of 12 months), respectively.
The ratio apoB/apoA-1 remained relatively stable and did not
change significantly over the study period. The TC, HDL,
and their ratio (AI) have been not assessed. Interestingly,
the authors found no associations between apoB/apoA-1
ratios and markers of disease activity, therefore sustaining
our hypothesis that ratios are less susceptible to changes in
disease activity and thus likely more proper to predict CV
risk in these patients. Finally, two more studies should be
mentioned, which further investigated the interplay between
rituximab and lipids in RA patients by assessing the eﬀects of
this drug on HDL antiatherogenic function [42, 43]. In the
first one, 49 RA patients have been followed 6 months after
receiving rituximab [43]. As previously suggested, rituximab
modestly increased HDL and apoA-1 levels and significantly
improved atherogenic index (P < 0.05). A subanalysis
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revealed that these changes were only present in the subgroup
of responders. There is no association found with the use
of prednisone. HDL composition changed upon rituximab
therapy, becoming depleted in SAA-1 in patients who have
demonstrated a good response to the therapy, rendering the
molecule to be anti-atherogenic. This observation further
substantiates the importance of HDL function assessment in
patients with RA and other chronic inflammatory conditions
in order to get a proper picture of their CV risk. In the
second study, Mathieu et al. presented data on 33 RA patients
treated with rituximab [42]. Atherogenic index remained
stable, although TC significantly increased both 6 and 12
months after rituximab (P < 0.001). The study enrolled RA
patients with longer disease duration (mean 17.6 years) who
have already fallen on two anti-TNF drugs.
4. Concluding Remarks
The available literature shows that anti-TNF drugs, IL-6R
antagonists, and anti-CD20 antibodies are able to modulate
the lipid profile in RA. Interestingly, when considering their
eﬀects on the atherogenic index and other lipoproteins ratio,
it becomes evident that changes in individual lipid levels
often do not translate into a change in AI, or are not
sustained long enough to significantly aﬀect the atherogenic
index. Therapy with etanercept, adalimumab, or rituximab
seems to have a positive impact on atherogenic index,
although this improvement does not always reach statistical
significance and sometimes an initial gain is lost over time.
In contrast, the use of infliximab may worsen lipid ratios on
the long term, though some report a neutral eﬀect. Similarly,
tocilizumab is likely to worsen lipid ratios in the first months
after therapy has been initiated, while the longer-term eﬀects
remain still unknown. Nevertheless, controlling disease
activity and achieving remission seem to beneficially impact
the lipid pattern, as suggested by the positive eﬀects seen in
responders. Finally, the form and function of HDL appear
to be compliant to changes in inflammation. Treatment with
anti-TNF agents and rituximab results in improvements of
the HDL antiatherogenic capacity. It is unclear whether these
changes progress over time and to what extent they decrease
the CV risk. No data on the eﬀects of tocilizumab on HDL
function are available.
The interpretation of our conclusions should not be
without caution. It is still unclear to what extent these
changes actually lead to a change in the CV risk. Moreover,
some suggest that even if changes occur, they might have a
milder impact degree on CV risk as compared to the general
population [52]. The follow-up period of these studies is
often too short to include CV events. Sometimes possible
confounding variables are not accounted properly for the
eﬀect on lipids, which is not a primary outcome for instance
in the majority of tocilizumab studies.
In conclusion, we suggest that atherogenic index and
HDL function are more suitable parameters of lipid profile
as determinants of CV risk in patients with RA, and perhaps
for other chronic inflammatory diseases including lupus,
psoriatic arthritis, and ankylosing spondylitis. The eﬀects
of biologicals on these parameters depend on the response
rate, concomitant prednisone use, duration of therapy, and
the biological self. If CV risk management will become an
integrated part of RA therapeutic strategies, and given the
increasing importance of personalized medicine, the choice
of biological might be done in the future also in accordance
with its own CV risk profile, where its eﬀect on lipids pattern
will become of crucial value, as presented above. Future
studies with clinical CV endpoints would have to address the
value of monitoring AI and HDL function during therapy
with biologicals in order to establish their real impact on CV
risk in these patients.
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